SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

Inclusion Criteria: * Diagnosis of B-cell non Hodgkin's lymphoma * Relapsed or refractory after standard treatments and with no curative option with conventional therapy (Patients having undergone stem cell transplantation may be included) * CD19 positive disease by flow cytometry or immunohistochemistry Exclusion Criteria: * Burkitt's lymphoma, Lymphoblastic lymphoma, Chronic lymphocytic leukemia (Small lymphocytic lymphoma may be included) * Evidence of cerebral or meningeal involvement by lymphoma * Patients without bi-dimensionally measurable disease * ECOG performance status \> 2 * Life expectancy less than 3 months * Chemotherapy or radiation therapy or other investigational agents within 4 weeks prior to entering the study * Previous radioimmunotherapy within 12 weeks * Known anaphylaxis to infused proteins * HIV, HBV and HCV positivity * Poor kidney, liver and bone marrow functions * Any serious active disease or co-morbid condition, which, in the opinion of the principle investigator, will interfere with the safety or the compliance with the study * Pregnant or breast-feeding women * Patients with reproductive potential without effective birth control methods The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.